Jacobson Orit, Weiss Ido D, Wang Lu, Wang Zhe, Yang Xiangyu, Dewhurst Andrew, Ma Ying, Zhu Guizhi, Niu Gang, Kiesewetter Dale O, Vasdev Neil, Liang Steven H, Chen Xiaoyuan
Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering.
Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases; National Institutes of Health, Bethesda, MD, USA.
J Nucl Med. 2015 Nov;56(11):1780-1785. doi: 10.2967/jnumed.115.160960. Epub 2015 Aug 27.
Protein tyrosine kinase-7 (PTK7), a member of receptor tyrosine kinase superfamily initially identified as colon carcinoma kinase-4, is highly expressed in various human malignancies. Its expression was found to correlate with aggressive biologic behaviors such as increased cell proliferation, invasiveness, and migration. Despite the importance and unmet need of imaging PTK7 in vivo, there is currently no clinically relevant method to visualize tumoral PTK7 expression noninvasively such as PET or SPECT. This study aimed to develop a specific, selective, and high-affinity PET radioligand based on single-stranded DNA aptamer to address this challenge.
Sgc8, a 41-oligonucleotide that targets to PTK7, was labeled with (18)F using a 2-step radiochemical synthesis, which featured a direct 1-step radiofluorination on the distinctive spirocyclic hypervalent iodine(III) precursor to give (18)F-fluorobenzyl azide followed by copper-mediated click conjugation with Sgc8-alkyne. (18)F-Sgc8 was evaluated in vitro and in vivo in 2 cell lines, HCT116 and U87MG, which express high and low amounts of PTK7, respectively.
Sgc8 was labeled efficiently with (18)F in an isolated radiochemical yield of 62% ± 2%, non-decay-corrected based on (18)F-fluorobenzyl azide. (18)F-Tr-Sgc8 was found to possess high-affinity binding to both cell lines, with binding affinity values of 2.7 ± 0.6 nM for HCT116 and 16.9 ± 2.1 nM for U87MG. In vivo PET imaging clearly visualized PTK7 expression in HCT116 xenografted mice, with tumor uptake of 0.76 ± 0.09 percentage injected dose per gram (%ID/g) at 30 min after injection for the subcutaneous tumor model and greater than 1.5 %ID/g for the liver metastasis model. U87MG xenograft tumors had much lower tracer accumulation (0.13 ± 0.06 %ID/g at 30 min after injection), which was consistent with the lower expression of PTK7 in this tumor model. The labeled aptamer was rapidly cleared from the blood through the kidneys and bladder to give high tumor-to-blood and tumor-to-muscle ratios of 7.29 ± 1.51 and 10.25 ± 2.08, respectively.
The (18)F-radiolabeling methodology shown here is a robust procedure for labeling aptamers and similar chemical moieties and can be applied to many different targets. Quantification of PTK7 using (18)F-Tr-Sgc8 may be suitable for clinical translation and might help in the future to select and monitor appropriate therapies.
蛋白酪氨酸激酶7(PTK7)是受体酪氨酸激酶超家族的成员,最初被鉴定为结肠癌激酶4,在多种人类恶性肿瘤中高表达。研究发现其表达与侵袭性生物学行为相关,如细胞增殖增加、侵袭性和迁移能力增强。尽管在体内对PTK7进行成像具有重要意义且需求未得到满足,但目前尚无像PET或SPECT这样的临床相关方法来无创可视化肿瘤PTK7表达。本研究旨在基于单链DNA适配体开发一种特异性、选择性和高亲和力的PET放射性配体,以应对这一挑战。
靶向PTK7的41个寡核苷酸Sgc8使用两步放射化学合成法用(18)F标记,其特点是在独特的螺环高价碘(III)前体上进行直接一步放射性氟化反应,生成(18)F - 氟苄叠氮,然后通过铜介导的点击反应与Sgc8 - 炔烃偶联。在两种细胞系HCT116和U87MG中对(18)F - Sgc8进行体外和体内评估,这两种细胞系分别高表达和低表达PTK7。
Sgc8以62%±2%的分离放射化学产率有效地用(18)F标记,基于(18)F - 氟苄叠氮未进行衰变校正。发现(18)F - Tr - Sgc8与两种细胞系都具有高亲和力结合,HCT116的结合亲和力值为2.7±0.6 nM,U87MG的为16.9±2.1 nM。体内PET成像清晰地可视化了HCT116异种移植小鼠中的PTK7表达,对于皮下肿瘤模型,注射后30分钟肿瘤摄取为0.76±0.09%注射剂量每克(%ID/g),对于肝转移模型大于1.5 %ID/g。U87MG异种移植肿瘤的示踪剂积累要低得多(注射后30分钟为0.13±0.06 %ID/g),这与该肿瘤模型中PTK7的低表达一致。标记的适配体通过肾脏和膀胱迅速从血液中清除,肿瘤与血液和肿瘤与肌肉的比率分别为7.29±1.51和10.25±2.08。
此处展示的(18)F放射性标记方法是标记适配体和类似化学部分的可靠程序,可应用于许多不同靶点。使用(18)F - Tr - Sgc8对PTK7进行定量可能适用于临床转化,未来可能有助于选择和监测合适的治疗方法。